NCT04008329Recruiting
A Registered Cohort Study on Amyotrophic Lateral Sclerosis
Source: ClinicalTrials.gov · Last updated 22 Mar 2021 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Amyotrophic lateral sclerosis (ALS) is a kind of motor neuron degeneration disorder without effective therapy. This registered cohort study will provide further insights into the clinical course of ALS, and investigate disease-relative risk factors and the genetic background of Chinese ALS patients.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2000 (estimated)
- First submitted
- 1 Jul 2019
- Start date
- 5 Jul 2019
- Primary completion date
- Jul 2029
- Lead sponsor
- First Affiliated Hospital of Fujian Medical University
- Diseases
- ALS (motor neurone disease)
- NCT number
- NCT04008329
What you commit to
- Study type: Observational
- Planned participants: 2000
- From 5 Jul 2019 to the primary completion date, Jul 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of serious head trauma or neuropsychiatric disease
Other
- Decline to participate
Who the study is looking for
- Amyotrophic Lateral Sclerosis patients fulfilling the El Escorial criteria (including definite, probable and possible)
- Progressive muscular atrophy
- Primary lateral sclerosis
- Progressive bulbar palsy
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Neurology, First Affiliated Hospital of Fujian Medical University Coordinator of this site? Confirm its status | Fuzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.